Clinical Trial Update: Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bemcentinib in combination with pembrolizumab in advanced non-small cell lung cancer has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• bemcentinib (BGB324) (bemcentinib)

Snippet

Sponsor: BerGenBio ASA | Conditions: Lung Cancer Metastatic, NSCLC Stage IV | Phase 2 | Status: COMPLETED | Results posted: 2025-09-25